Estrategias para reducir la resistencia | 08 ENE 19

Uso racional de antibióticos

Estrategias para minimizar la resistencia a los antibióticos y maximizar su eficacia
Autor/a: Cheston B. Cunha, MD*, Steven M. Opal.  Med Clin N Am 102 (2018) 831–843
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1. Cunha CB, Varughese CA, Mylonakis E. Antimicrobial stewardship programs (ASPs): the devil is in the details. Virulence 2013;4:147–9.

2. Hurford A, Morris AM, Fisman DN, et al. Linking antimicrobial prescribing to antimicrobial resistance in the ICU: before and after an antimicrobial stewardship program. Epidemics 2012;4:203–10.

3. Rimawi RH, Mazer MA, Siraj DS, et al. Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. Crit Care Med 2013;41:2099–107.

4. Njoku JA, Hermsen ED. Antimicrobial stewardship in the intensive care unit: a focus of potential pitfalls. J Pharm Pract 2010;23:50–60.

5. Amer MR, Akhras NS, Mahmood WA, et al. Antimicrobial stewardship program implementation in a medical intensive care unit at a tertiary care hospital in Saudi Arabia. Ann Saudi Med 2013;33:547–54.

6. Vincent JL, Opal SM, Marshall JC, et al. Sepsis definitions: time for change. Lancet 2013;381:774–5.

7. Singer M, Deutschman CS, Seymour CW, et al. The third international  onsensus

definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801–10.

8. Erdem H, Inan A, Altindis S, et al. Surveillance, control and management of infections in intensive care units in Southern Europe, Turkey and Iran—a prospective multicenter point prevalence study. J Infect 2014;68:131–40.

9. Frakking FN, Rottier WC, Dorigo-Zetsma JW, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-b-lactamase-producing bacteria. Antimicrob Agents Chemother 2013;57:3092–9.

10. Martinex MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 2012;56:2795–805.

11. Papadimitriou-Oliveris M, Marangos M, Fligou F, et al. KPC- producing Klebsiella pneumoniae enteric colonization acquired during intensive care unit stay: the significance of risk factors for its development and its impact on mortality. Diagn Microbiol Infect Dis 2013;77:169–73.

12. Pogue JM, Marchaim D, Kaye D, et al. Revisiting “older” antimicrobials in the era of multidrug resistance. Pharmacotherapy 2011;31:912–21.

13. Kahlmeter G. Defining antibiotic resistance-towards international harmonization. Ups J Med Sci 2014;119:78–86.

14. Baquero F, Coque TM, Canton R. Counteracting antibiotic resistance: breaking barriers among antibacterial strategies. Expert Opin Ther Targets 2014;31:1–11.

15. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility reakpoints. Clin Microbiol Infect 2007;20:391–408.

16. Domenico P, O’Leary R, Cunha BA. Differential effects of bismuth and salicylate salts on the antibiotic susceptibility of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1992;11:170–5.

17. Cunha BA. Problems arising in antimicrobial therapy due to false susceptibility testing. J Chemother 1997;1:25–35.

18. Cunha BA. Minocycline versus doxycycline for methicillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents 2010;35:517–8.

19. Cunha BA, editor. Antibiotic essentials. 12th edition. Sudbury (MA): Jones & Bartlett; 2013.

20. Lodise TP, Butterfield J. Use of pharmacodynamic principles to inform b-lactam dosing: “S” does not always mean success. J Hosp Med 2011;6:S16–23.

21. Cunha BA. Clinical relevance of penicillin-resistant Streptococcus pneumoniae. Semin Respir Infect 2002;17:204–14.

22. Pop-Vicas A, Opal SM. The Clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock. Virulence 2014;5:206–12.

23. Cunha BA. Antibiotic resistance: effective control strategies. Lancet 001;357: 1307–8, 1101.

24. Cunha BA. Strategies to control antibiotic resistance. Semin Resp Infect 2000;21: 3–8.

25. Cunha BA. Antibiotic tissue penetration. Bull N Y Acad Med 1983;59:443–9.

26. Cunha BA. Antibiotic resistance control in the CCU. In: Cunha BA, editor. Infectious diseases in critical care medicine. 2nd edition. New York: Informa Healthcare; 2007. p. 609–24.

27. Opal SM. ACP journal club. Review: short-course antibiotics in hospital-acquired pneumonia do not affect mortality. Ann Intern Med 2012;156:JC3–13.

28. Ambrose PG, Owens RC Jr, Quintiliani R, et al. Antibiotic use in the critical care unit. Crit Care Clin 1998;14:283–308.

29. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill atient.

Crit Care Med 2009;37(3):840–51.

30. Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 2009;66:S23–30.

31. Winterboer TM, Lecci KA, Olsen KM. Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients. J Pharm Pract 2010;23:6–18.

32. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of “bug and drug.” Nat Rev Microbiol 2004;2:289–300.

33. Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. Clin Microbiol Infect 2000;6:270–3.

34. Cunha BA. Vancomycin revisited: a reappraisal of clinical use. Crit Care Clin 2008;24:393–420.

35. Goff DA, Nicolau DP. When pharmacodynamics trump costs: an antimicrobial stewardship program’s approach to selecting optimal antimicrobial agents. Clin Ther 2013;35:766–71.

36. Roberts JA, Pharm B, Kruger P, et al. Antibiotic resistance – what’s dosing got to do with it? Crit Care Med 2008;36:2433–40.

37. Noreddin AM, Elkhatib WF. Levofloxacin in the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther 2010;8:505–14.

38. Gous A, Lipman J, Scibante J, et al. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 2005;26:50–5.

39. Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother 2010;65:1725–32.

40. Roberts JA, Lipman J. Optimizing use of beta-lactam antibiotics in the critically ill. Semin Respir Crit Care Med 2007;28:579–85.

41. McKinnon PS, Paladine JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008;31:345–51.

42. Roberts JA, Paratz J, Paratz E, et al. Continuous infusion of beta lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007;30:111–8.

43. Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a- day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2006;59:285–91.

44. Ogutlu A, Guclu E, Karabay O, et al. Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients. Ann Clin Microbiol Antimicrob 2014;13:7.

45. Palmore TN, Henderson DK. Carbapenem-resistant Enterobacteriaceae: a call for cultural change. Ann Int Med 2014;160:567–70.

46. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin

without toxicity. Heart Lung 2006;35:207–11.

47. Cunha BA, Mickail N, Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart & Lung 2007;36:456–61.

48. Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and nonmultidrug- resistant gram-negative bacteremias. J Chemother 2007;19:232–3.

49. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrugresistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009;47:1613.

50. Shoai Tehrani M, Hajage D, Fihman V, et al. Gram-negative bacteremia: which empirical antibiotic therapy? Med Mal Infect 2014;44:159–66.



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2020